Literature DB >> 30554040

Long-term disability in neuromyelitis optica spectrum disorder with a history of myelitis is associated with age at onset, delay in diagnosis/preventive treatment, MRI lesion length and presence of symptomatic brain lesions.

Maureen A Mealy1, Sarah E Mossburg2, Su-Hyun Kim3, Silvia Messina4, Nadja Borisow5, Reydmar Lopez-Gonzalez6, Juan Pablo Ospina7, Michael Scheel5, Anusha K Yeshokumar8, Amine Awad4, M Isabel Leite4, JorgeA Jimenez Arango6, Friedemann Paul5, Jacqueline Palace4, Ho Jin Kim3, Michael Levy7.   

Abstract

BACKGROUND: Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease of the central nervous system (CNS) that preferentially targets the spinal cord and optic nerves. Increasing disability is accrued with each inflammatory attack. Disability has been shown to be an independent predictor of poor quality of life in those with NMOSD. Factors associated with increasing disability need further systematic investigation.
METHODS: We performed a multi-center retrospective chart analysis of aquaporin-4 (AQP4) seropositive NMOSD patients with a history of myelitis seen at five large referral centers for patients with NMOSD worldwide for whom thorough records including relapse history and corresponding imaging were available. Potential contributors to long-term disability were extracted including demographics, radiographic findings, and clinical characteristics. Multivariable regression modeling was conducted to determine correlates of disability in patients with NMOSD, as measured by the Expanded Disability Status Scale (EDSS).
RESULTS: One hundred eighty-two AQP4 seropositive patients (88% female) were included in this analysis. Multiple regression modeling revealed that older age at disease onset, delay in diagnosis/preventive treatment, length of longest acute myelitis lesion and presence of symptomatic brain/brainstem lesions were associated with increased disability when holding other variables constant.
CONCLUSION: While age at onset is a factor that cannot be controlled in NMOSD, we can reduce the delay in diagnosis/preventive treatment and reduce future relapses in the brain/brainstem and spinal cord. Delay in diagnosis/preventive treatment and imaging variables that contributed to increased disability support the need for improved measures for early, accurate diagnosis and management of NMOSD, and aggressive treatment of acute relapses.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Keywords:  Devic's; Disability; EDSS; MRI; NMOSD

Mesh:

Year:  2018        PMID: 30554040      PMCID: PMC6397677          DOI: 10.1016/j.msard.2018.12.011

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN: 2211-0348            Impact factor:   4.339


  14 in total

Review 1.  A window into the future? MRI for evaluation of neuromyelitis optica spectrum disorder throughout the disease course.

Authors:  Jacqueline M Solomon; Friedemann Paul; Claudia Chien; Jiwon Oh; Dalia L Rotstein
Journal:  Ther Adv Neurol Disord       Date:  2021-05-09       Impact factor: 6.570

2.  Late Onset of Neuromyelitis Optica Spectrum Disorders.

Authors:  Yara Dadalti Fragoso; Heloisa Helena Ruocco; Ronaldo Maciel Dias; Hideraldo Cabeça; Ricardo Gonçalves; Nise A de Carvalho Sousa; Caroline Vieira Spessotto; Carlos Bernardo Tauil; Soniza Vieira Alves-Leon; Sidney Gomes; Marcus Vinicius M Gonçalves; Suzana C Nunes Machado; Andrea Anacleto; Eber Castro Correa; Maria Lucia V Pimentel; Gutemberg Augusto C Santos
Journal:  Neurol Ther       Date:  2019-07-02

3.  Comparison of Clinical Outcomes of Transverse Myelitis Among Adults With Myelin Oligodendrocyte Glycoprotein Antibody vs Aquaporin-4 Antibody Disease.

Authors:  Romina Mariano; Silvia Messina; Kurun Kumar; Wilhelm Kuker; Maria Isabel Leite; Jacqueline Palace
Journal:  JAMA Netw Open       Date:  2019-10-02

4.  Predictive Factors of Resistance to High-Dose Steroids Therapy in Acute Attacks of Neuromyelitis Optica Spectrum Disorder.

Authors:  Chuan Qin; Ran Tao; Shuo-Qi Zhang; Bo Chen; Man Chen; Hai-Han Yu; Yun-Hui Chu; Ke Shang; Long-Jun Wu; Bi-Tao Bu; Dai-Shi Tian
Journal:  Front Neurol       Date:  2020-11-12       Impact factor: 4.003

5.  Plegia to walking: AHSCBMT in severe NMOSD relapse.

Authors:  Nicola Carlisle; Parameswaran Hari; Staley Brod
Journal:  BMJ Neurol Open       Date:  2020-10-26

6.  Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder.

Authors:  Romain Marignier; Jeffrey L Bennett; Ho Jin Kim; Brian G Weinshenker; Sean J Pittock; Dean Wingerchuk; Kazuko Fujihara; Friedemann Paul; Gary R Cutter; Ari J Green; Orhan Aktas; Hans-Peter Hartung; Fred D Lublin; Ian M Williams; Jorn Drappa; Dewei She; Daniel Cimbora; William Rees; Michael Smith; John N Ratchford; Eliezer Katz; Bruce A C Cree
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-03-26

7.  PLEX: the best first-line treatment in nmosd attacks experience at a single center in Colombia.

Authors:  C Restrepo-Aristizábal; L M Giraldo; Y M Giraldo; A M Pino-Pérez; F Álvarez-Gómez; C A Franco; J V Tobón; J L Ascencio; M I Zuluaga
Journal:  Heliyon       Date:  2021-04-17

8.  HLA genotype-clinical phenotype correlations in multiple sclerosis and neuromyelitis optica spectrum disorders based on Japan MS/NMOSD Biobank data.

Authors:  Mitsuru Watanabe; Yuri Nakamura; Shinya Sato; Masaaki Niino; Hikoaki Fukaura; Masami Tanaka; Hirofumi Ochi; Takashi Kanda; Yukio Takeshita; Takanori Yokota; Yoichiro Nishida; Makoto Matsui; Shigemi Nagayama; Susumu Kusunoki; Katsuichi Miyamoto; Masanori Mizuno; Izumi Kawachi; Etsuji Saji; Takashi Ohashi; Shun Shimohama; Shin Hisahara; Kazutoshi Nishiyama; Takahiro Iizuka; Yuji Nakatsuji; Tatsusada Okuno; Kazuhide Ochi; Akio Suzumura; Ken Yamamoto; Yuji Kawano; Shoji Tsuji; Makoto Hirata; Ryuichi Sakate; Tomonori Kimura; Yuko Shimizu; Akiko Nagaishi; Kazumasa Okada; Fumie Hayashi; Ayako Sakoda; Katsuhisa Masaki; Koji Shinoda; Noriko Isobe; Takuya Matsushita; Jun-Ichi Kira
Journal:  Sci Rep       Date:  2021-01-12       Impact factor: 4.379

Review 9.  Update on neuromyelitis optica spectrum disorder.

Authors:  Kathryn B Holroyd; Giovanna S Manzano; Michael Levy
Journal:  Curr Opin Ophthalmol       Date:  2020-11       Impact factor: 4.299

Review 10.  Review of approved NMO therapies based on mechanism of action, efficacy and long-term effects.

Authors:  Staley A Brod
Journal:  Mult Scler Relat Disord       Date:  2020-10-07       Impact factor: 4.339

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.